Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 16.82
- Piotroski Score 6.00
- Grade Market Perform
- Symbol (PNT)
- Company POINT Biopharma Global Inc.
- Price $12.50
- Changes Percentage (0.16%)
- Change $0.02
- Day Low $12.49
- Day High $12.51
- Year High $14.35
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/22/2024
- Fiscal Year End N/A
- Average Stock Price Target $14.00
- High Stock Price Target $17.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.10
- Trailing P/E Ratio 11.363636363636
- Forward P/E Ratio 11.363636363636
- P/E Growth 11.363636363636
- Net Income $98.29 M
Income Statement
Quarterly
Annual
Latest News of PNT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Does Pennant Group (NASDAQ:PNTG) Deserve A Spot On Your Watchlist?
Investors often buy shares in loss-making companies with promising stories, risking their capital. However, focusing on profitable companies like Pennant Group (NASDAQ:PNTG) can offer more stability. ...
By Yahoo! Finance | 1 week ago -
SiriusPoint Ltd (SPNT) Q3 2024 Earnings Call Highlights: Strong Underwriting Performance Amidst ...
Hurricane Milton is expected to cause $30 to $40 million in losses for SiriusPoint, reflecting 1.2% to 1.6% of their opening book value for the fourth quarter....
By Yahoo! Finance | 1 week ago -
SiriusPoint Ltd. (SPNT) Stock Price, News, Quote & History
SiriusPoint Ltd. reports strong financial results with a seventh consecutive quarter of underwriting profits and $109.9m in net income. The company's half-year core combined ratio improved to 92.5%, s...
By Yahoo! Finance | 1 month ago
